Yemeni students are the silent victims of Lebanons crisis – TRT World

Lebanon has kept its borders open for war-affected Yemenis, many of whom struggle to get by as the country grapples with economic chaos.

When Ahmed* travelled to Lebanon from Taiz in Yemen in 2014, he had high hopes for his career and future.

He enrolled for a degree in biochemistry at a Lebanese university, thanks to a government scholarship that covered his fees and accommodation. At the time, his parents were able to send him a basic maintenance stipend. But that came to an end two years later, despite the familys best efforts. Taiz, Yemens third-largest city, had become the theatre of some of the fiercest fighting in the seven-year war between Iran-aligned Houthi rebels and government forces backed by a Saudi-led coalition. He had to become a lifeline for his family back home.

After what happened in Yemen things became so tough for them, the 26-year-old told TRT World from Beirut, music blasting in the background of the shop where hes been working for the past few months. So I dropped out of college and started working. Illegally, of course.

Since then, Ahmed says hes been hopping from job to job in order to send the much-needed remittance money to his family in Yemen. But as Lebanons economic crisis grinds on, leaving 80 percent of its population living below the poverty line, keeping afloat has become a daily struggle. The Lebanese currency has lost as much as 90 percent of its value since 2019, while inflation has skyrocketed and the average cost of food increased by more than 400 percent between October 2019 and June 2021.

I am working on finding better opportunities to work in another place, as its so difficult in Lebanon, Ahmed says, We get paid so little, approximately 30 dollars a month. I used to be able to send money to my family, but now I am only covering my living expenses.

Every year, hundreds of students from Yemen study at Lebanese universities, accounting for the largest chunk of the Yemeni community in the country, estimated at around 500. But no one is keeping an official count and Lebanon has remained one of the few countries in the world that Yemen citizens can enter on a tourist visa they can get upon arrival at Beirut airport - provided they can show they are carrying $2,000 in cash and proof of a hotel booking.

Since the start of the war, Yemeni students in Lebanon have seen their sources of support dry up whether its government scholarship payments that no longer come in regularly, or family income sources depleted due to the ongoing economic crisis in the country, where millions are food insecure and at risk of famine.

Yemeni students have protested a number of times over the years to raise their concerns, but their voices have been largely ignored. The economic crisis in Lebanon has only contributed to a deterioration of the situation, as those, like Ahmed, who are forced to drop out and find work mostly have no choice but to join the informal labour force.

When you go apply for a student residence permit at the General Security Office, they ask you to sign an official document that you're not going to be working in Lebanon, says Ali Al-Dailami, a researcher at the Sanaa Center for Strategic Studies. Applying for a work permit is possible only upon meeting certain conditions including receiving pre-approval before arrival in Lebanon. And if you get caught, you can get deported, Al-Dailami says.

From student to unrecognized refugee

Al-Dailamis research into the Yemeni community in Lebanon found that some students have decided to approach the UNHCR instead to apply for asylum and resettlement.

When students find their families can't provide for them anymore, what they do is they go to apply because they need support, Al-Dailami says.

The number of Yemeni asylum seekers registered with the UNHCR in Lebanon remains negligible, however just 104 in 2020. An additional 25 had been recognised refugee status. Many, Al-Dailami says, see the process as daunting, long and leading nowhere, particularly as resettlement options are limited. While four million people have been uprooted due to the crisis in Yemen, Yemenis did not figure among the top ten nationalities resettled in the EU in 2020.

This country has placed more powerful and wealthier states to shame by opening the doors to lots of refugees from these war zones in the region, Al-Dailami says. A country of barely seven million, Lebanon hosts more refugees per capita than anywhere else in the world, the majority being Syrians.

Ahmed plans to find a way to resume his studies in biochemistry.

I dont know how many years its going to take me to graduate, he says, but I think leaving Lebanon at this time is better. I may find other opportunities for work that allow me to continue my studies.

We are not treated like Lebanese students, we have to pay [our student fees] in dollars now, he adds.

Going back to his worn-torn country is not an option either, particularly as, he says, having lived in Lebanon means hed be seen as taking sides.

Lebanon is safe, for now. You can live here, but you need fresh dollars from outside, he says. You work, you pay for your food and your stay. There is nothing much else you can do.

[Note: Ahmed* is a pseudonym used to protect his identity due to his status.]

Source: TRT World

Read the original post:
Yemeni students are the silent victims of Lebanons crisis - TRT World

Feeling stressed? This ‘weird’ technique can help – and here is how you can learn it easily – Economic Times

The technique is known as Emotional Freedom Techniques (EFT). It's commonly called tapping because the technique stimulates acupressure points on the face and body with a gentle two-finger tapping process.

What is the evidence for tapping?The evidence for this simple approach to stress reduction has been growing exponentially.

Research now shows tapping is beneficial for food cravings, depression, anxiety, phobias and post-traumatic stress disorder.

What is even more interesting is that tapping affects the body's biochemistry such as immunity and blood pressure. Just one hour of tapping decreases the stress hormone cortisol by 43%.

It's suggested tapping affects the stress centre in the brain (the amygdala) and the memory centre (the hippocampus). Both play a role in the decision-making process when someone decides if something is a threat.

Research has now examined primary school children who have used tapping in schools and found it helps with their focus and concentration.

So how can you get started?Usually tapping is done when you have a feeling you would like to reduce. If you feel stressed, this would be a perfect time to start tapping. There are five steps:

Step 1. Rate your level of stress out of ten, where ten is the highest level and zero would represent complete calm. You can guess this number as it is just a way of you rating your feeling.

Step 2. People should state their feeling out loud in order to engage with it and pay attention to how you feel. Typically, you would say:

Even though I feel really stressed at the moment because of ______, I accept this is how I feel.

It is important to be specific about why you feel stressed and think about that as you do the tapping process. As you say this statement out loud, tap on the point at the side of the hand, as shown below.

Saying your problem out loud will not reinforce it; you are actually being honest with yourself in this moment and acknowledging how you feel.

Step 3. Tap with two fingers through the eight acupoints shown below and just say the feeling (not the whole sentence). For example, you may say feel stressed while you think about what is making you feel stressed in that moment.

Step 4. When you finish tapping on the last acupoint (top of the head), pause and take a breath. Re-rate your level of stress after that single round.

Step 5. If your rating out of ten is still high, continue tapping as many rounds as you want until it feels lower in number, or you notice a shift. If you were to think of other feelings as you are tapping, you can change the words.

For example, you might start tapping on feeling stressed about a work task, but after a few rounds you notice you really feel overwhelmed and wishing you had support. You can change the words to reflect this and say I feel overwhelmed instead.

The underlying mechanism is that the tapping at these acupoints sends activating or deactivating signals to brain areas that have been aroused by the phrases. Tapping generates these electrical signals via the principle of mechanosensory transduction.

As a brief intervention that can be self-applied, tapping is now backed by more than 100 randomised clinical trials (the most accepted form of research).

It appears highly effective and rapid compared to conventional treatments.

So, while it may look a little strange, tapping is equivalent or comparable to gold-standard approaches such as Cognitive Behavioural Therapy (CBT). It's worth trying next time you feel stressed!

(This article is syndicated by PTI from The Conversation)

Go here to see the original:
Feeling stressed? This 'weird' technique can help - and here is how you can learn it easily - Economic Times

Researchers discover new function of protein tBID – News-Medical.net

The protein tBID can trigger programmed cell death (apoptosis) by inducing damage in the energy suppliers of the cells, the mitochondria. Apoptosis is essential for maintaining tissue balance. In addition, apoptosis plays a critical role as a defense mechanism and in the elimination of damaged or redundant cells in our bodies. Impaired apoptosis has been linked to many human diseases, from cancer and autoimmune diseases to neurological disorders and heart failure. The discovery by Professor Dr Ana Garcia-Saez and her collaborators and colleagues at the University of Cologne's CECAD Cluster of Excellence for Aging Research that tBID, previously thought to be a signal transducer, can also execute apoptosis could open up new therapies to treat malignant cells such as cancer cells. The article 'tBID can act as a BAX-like effector of apoptosis' has now been published in The EMBO Journal.

The protein tBID belongs to the family of BCL-2 proteins, which are fundamentally important for the self-determined apoptosis of cells and tissue balance. Because of the overlapping functions of this protein family, studying them individually is particularly challenging. Garcia-Saez and her team set out to characterize the roles of the various family members. Using cell lines lacking much of the BCL-2 proteins, they were able to determine the function of tBID. In addition, state-of-the-art microscopy (confocal, STED and electron microscopy) was used to analyze in detail the effects of tBID at the mitochondrial membrane in the cell. Activating tBID was also able to combat cellular infection with the bacterium Shigella flexneri and kill blood cancer cells (leukemia). In addition, the researchers showed that apoptosis triggered by tBID is independent of other known apoptosis induction pathways.

'For us, it was amazing to see that proteins which are quite well known still surprise us after four decades. The realization that a protein that was considered a signal transducer for twenty years has an effector function under certain conditions is mind-blowing,' Garcia-Saez remarked. This newly discovered function of tBID could in the future become useful in medicine.

For example, activating tBID could induce apoptosis when other known apoptosis signaling pathways fail or lack the proteins that carry it out. Activating tBID could also help with Shigella infections, where the proteins that usually induce apoptosis are not activated."

Professor Dr Ana Garcia-Saez, University of Cologne's CECAD Cluster of Excellence for Aging Research

The work for this study started at the IFIB (Interfaculty Institute of Biochemistry) in Tbingen and was further developed at the CECAD Research Center, Institute for Genetics, in Garcia-Saez's core laboratory, together with the laboratories of Professor Dr Hamid Kashkar und Dr Lukas Frenzel as well as external collaborators from the University of Nebraska and the laboratory of Andreas Villunger (University of Innsbruck and CeMM Research Center, Austria).

Source:

Journal reference:

Flores-Romero, H., et al. (2021) tBID can act as a BAX-like effector of apoptosis. The EMBO Journal. doi.org/10.15252/embj.2021108690.

See the rest here:
Researchers discover new function of protein tBID - News-Medical.net

21 Interesting Knox Students and Alumni We Met in 2021 – Knox College

Cecilia Pinto 81 (1) is a fiction writer and teaching artist. Her novella, Imagine the Dog, won the 2020 Clay Reynolds Novella Prize. Severalcurrent students received prestigious awards this year.Becca Gadiel 22 (2) was chosen as Knox Colleges 2021-22 Student Laureate of the Lincoln Academy of Illinois.Sophia Bowley 22 (3)received the Faculty Scholarship Prize at Knoxs 2021 Opening Convocation ceremony, andKyle Williams 22 (4), was awarded a scholarship from the National Association of Black Journalists Chicago Chapter.

In the fall of 2021, new minors were introduced to the Knox academic programsone of them being Spanish translation and interpreting. Eric Espinoza 23 (5) is an exemplary student for the new minor, having volunteered for different projects and clinics, as well as being hired by Worldwide Languages as an interpreter.

In the always advancing world of technology, two alumni we met in 2021 have centered their careers around software. Ginny Graves 10 (6) leads a team with a start-up, Association Analytics, which provides business intelligence software to the association market. Harry Carpenter 18 (7) has been developing life insurance and annuities software for LIDP.

The business and management major is now a top program at Knox. Current students Elijah Crump 22 (8) and Andrew Hand 22 (9), are both majors and have had significant success and opportunities in the program. Crump connected with a Knox alumnus and worked in finance during a summer internship. Hand came to Knox as a transfer student, and found Knox was the perfect fit for him by working with the business and management faculty. While majoring in computer science, Kam Wells 17 (10) minored in business and management and a self-designed minor in the analytics of athletics. Wells is currently a data engineer for the Boston Red Sox, combining his interests in baseball and computer science.

Though they may not have majored in business at Knox, Khyati Shah 99 (11) and Pamela Hernandez 22 (12) both have successful careers in the corporate world. Shah is currently senior vice president of corporate communications at Kinara Capital, a company driving financial inclusion of small business entrepreneurs in India. The company was founded by Knox alumna Hardika Shah 99, Khyatis sister and CEO of Kinara Capital. As an entrepreneur, Hernandez has launched her own social science research firm, Educo Research.

The pandemic shone a light on how very important teachers are in ensuring future generations receive the education they need, even in almost impossible situations. Knox has accomplished alumni filling that need. Jason Maclin 07 (13) is currently the principal at Vista PEAK Preparatory in Colorado, and he finds his time of being a principal and educator during a pandemic to be enlightening. Recent graduate Katy Coseglia 20 (14) discovered the opportunity to teach in a school district in a village in Alaska and has enjoyed learning from the people in the village and teaching her students new skills.

Being as involved as possible is how Melvin Taylor 14 (15) describes his time since graduating from Knox. After working in several different roles and career paths, Taylor is currently working as a writer at Heavy.com, an online news platform that covers breaking news, sports, entertainment, and shopping.

In the sciences, Natalee Young Hau 13 (16), who majored in biology, reignited her passion for science when she started working as a medical laboratory technologist during the pandemic. Britney Salinas 22 (17) is majoring in biochemistry and is taking the opportunity to conduct research in a new collaborative program by working on the Solutions of Nature project on the Knox Farm. After graduating from Knox with a degree in biochemistry,Taliah Ellis 19 (18) attends medical school and plans on a career in orthopedic surgery and sports medicine.

Jessie Johnson 12 (19), and Jon Gripshover 06 (20) are in different careers than they pictured when they arrived at Knox. Johnson is the founder and CEO of a successful food blog called Life As A Strawberry. Gripshover has opened Accessibility Compliance Testing Services, which is a new program in California Prison Industry Authoritys digital services division.

Knox students are so dedicated to learning that some started coming to Knox even before they graduated high school. Emma Curry 24 (21) took advantage of the Early College program, leading her to her decision to attend Knox.

2021 was a year that showed us that nothing can keep the Knox community from reaching new heights on and off campus. The resilience and determination of our community continues to shine, as it has for almost 185 years.

See the rest here:
21 Interesting Knox Students and Alumni We Met in 2021 - Knox College

Lung Cancer Research Advocacy Driven by Heart – Curetoday.com

Upal Basu Roy is currently the senior director of LUNGevity Research at the LUNGevity Foundation. He holds a Ph.D. in molecular and cellular biology from the University of Arizona in Tucson and an M.P.H. in global health policy and management from New York University.

In his official capacity, he spearheads LUNGevitys Translational Science Research Programs and its Patient-Focused Research Center. The research programs he develops and manages, such as Project Transform and Project PEER, focus on capturing the experience and perspective of patients with lung cancer in a way that will improve treatment and patient care for all lung cancer types. His LUNGevity work also includes overseeing its research awards program, participating in the Health Equity Council, guiding the scientific program of its International Lung Cancer Survivorship Conference, tracking developments in lung cancer care and translating new research into patient-friendly materials. He also provides patient perspective to government agencies, academia and industry, such as exploring ways to make clinical trials more accessible to a wider variety of patients.

In addition to an in-depth understanding of lung cancer science and research, Upal has a real heart for patients. He has generously given his personal as well as professional time to serve on an institutional review board, address disparities in cancer care, educate individual patients and help them navigate cancer drug access issues in other countries, and facilitate several patient-driven initiatives. For example, he helped create Project PRIORITY a collaboration between LUNGevity Foundation and EGFR Resisters to capture the lived experience of patients who have EGFR-positive lung cancer and analyzed data for presentations. Another example is helping the patient group ALK Positive develop their research grant awards process. Additionally, he served as a volunteer mentor for the new International Association for the Study of Lung Cancers Supportive Training for Advocates on Research and Science (STARS) program, which helps lung cancer advocates evolve into research advocates, and he developed a STARS training module for small cell lung cancer.

Most of Upals work happens behind the scenes and does not get the same visibility as aware- ness campaigns and policy advocacy. However, his work is essential for improving outcomes for all patients with lung cancer. He deserves the highest appreciation and recognition from the entire lung cancer community.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

See original here:
Lung Cancer Research Advocacy Driven by Heart - Curetoday.com

Dental mesenchymal stromal/stem cells in different microenvironments implications in regenerative therapy – Newswise

Current research data reveal microenvironment as a significant modifier of physical functions, pathologic changes, as well as the therapeutic effects of stem cells. When comparing regeneration potential of various stem cell types used for cytotherapy and tissue engineering, mesenchymal stem cells (MSCs) are currently the most attractive cell source for bone and tooth regeneration due to their differentiation and immunomodulatory potential and lack of ethical issues associated with their use. The microenvironment of donors and recipients selected in cytotherapy plays a crucial role in regenerative potential of transplanted MSCs, indicating interactions of cells with their microenvironment indispensable in MSC-mediated bone and dental regeneration. Since a variety of MSC populations have been procured from different parts of the tooth and tooth-supporting tissues, MSCs of dental origin and their achievements in capacity to reconstitute various dental tissues have gained attention of many research groups over the years. This review discusses recent advances in comparative analyses of dental MSC regeneration potential with regards to their tissue origin and specific microenvironmental conditions, giving additional insight into the current clinical application of these cells.

Core Tip: This review discusses recent advances in comparative analyses of dental mesenchymal stem cell (MSC) regeneration potential. We have summarized the available research evidence concerning the effects of hypoxic and inflammatory microenvironmental factors on dental MSC differentiation capacity. Existing investigations indicate the very important aspect of the recipient microenvironment niche in terms of therapeutic efficacy of transplanted dental MSCs. However, some of the data for the same cell type (especially in hypoxic in vitro conditions) are conflicting, so it is important to point out that the biology of MSCs is not yet fully known, and further research in this area is needed.

See the original post here:
Dental mesenchymal stromal/stem cells in different microenvironments implications in regenerative therapy - Newswise

Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML – BioSpace

FLORHAM PARK, N.J., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).

The majority of patients with AML continue to have poor long-term outcomes, particularly those who suffer relapse or have measurable residual disease, necessitating development of novel therapies, including CYNK-001, said Andrew Pecora, M.D., President of Celularity. Robert Hariri, M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity added, We believe that the unique properties of our cell source, including the ability to proliferate and maintain activity, could be the key to improving response rates and durability for patients. We are pleased to receive this fast-track designation from the FDA for AML supporting continued development of our placental-derived NK cell platform. CYNK-001 previously received orphan drug designation for malignant gliomas and fast track designation for glioblastoma multiforme.

About Fast Track Designation

Fast Track Designation is an FDA process designed to facilitate the development and expedite the review of new drugs that are intended to treat a serious condition and have the potential to address unmet medical needs. The purpose of Fast Track designation is to expedite the process of getting important new drugs to patients. The designation may offer frequent interactions with the FDA review team on the products development and the product may be eligible for rolling review and priority review if certain criteria are met.

About CYNK-001

Celularitys lead therapeutic program based on its placental-derived unmodified NK cell type is CYNK-001, an allogeneic unmodified NK cell being developed as a treatment for hematologic malignancies, solid tumors, and infectious diseases. CYNK-001 is a cryopreserved allogeneic off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells. The safety and efficacy of CYNK-001 have not been established, and CYNK-001 has not been approved for any use by the U.S. Food and Drug Administration or any other analogous regulatory authority.

About Celularity

Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placentas unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

To learn more, visit celularity.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are forward-looking statements, including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as anticipate, believe, can, contemplate, continue, could, estimate, expect, forecast, intends, may, might, outlook, plan, possible, potential, predict, project, seek, should, strive, target, will, would and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include, statements regarding the ability to improve response rates and durability, and other statements regarding the development of CYNK-001, and Celularitys ability to develop effective, accessible and affordable therapies, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel cellular therapies, and the clinical trial and regulatory approval process; and risks associated with developments relating to Celularitys competitors and industry, along with those risk factors set forth under the caption Risk Factors in Celularitys proxy statement/prospectus filed with the Securities and Exchange Commission (SEC) on August 12, 2021 and other filings with the SEC. These risks and uncertainties may be amplified by the COVID- 19 pandemic. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularitys current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularitys views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Celularity Investor Contacts:Carlos Ramirez SVP, Investor RelationsCelularity Inc.carlos.ramirez@celularity.com

Celularity Media ContactJason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

See more here:
Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML - BioSpace

Doesn’t an excessive intake of simple sugar affect higher brain function? – EurekAlert

image:Excessive sucrose intake during adolescence cause cellular damage in non-neuronal cell groups, inhibiting the uptake of glucose from the blood into the brain parenchyma, leading to dysfunctions of certain neurons that cause the major symptoms of psychiatric disorders. view more

Credit: TMIMS

There has been a remarkable increase in intake of simple sugar (sucrose, isomerized sugar (corn syrup)) from beverages and diets in modern society. The intake of simple sugars in adolescents in which mental disorders frequently occur is higher than any other generations. Moreover, patients with mental disorders consume approximately 2-fold more sugar than age-matched healthy individuals, and patients with schizophrenia who consume more sucrose exhibit more severe symptoms. Despite accumulating evidence, it is still unproven that excessive sugar intake contributes to the pathogenesis of psychiatric disorders among susceptible individuals. Doesn't an excessive intake of simple sugar affect higher brain function? We attempted to elucidate this causal relationship.

As a susceptibility gene for psychiatric disorder, we selected Glyoxylase-1 and Disrupted-in-schizophrenia-1. By combining the heterozygous mice with environmental factors of excessive sugar intake at the age of puberty, we successfully created a novel mouse model exhibiting various mental disorder-like symptoms, including decreased sensorimotor gating function, decreased working memory, hyperactivity, abnormal gamma-band component in EEG. In other words, this demonstrates a possibility that the excessive intake of simple sugar at the age of puberty could be an environmental risk factor of psychiatric disorders.

Furthermore, by analyzing this model mouse, we aimed to identify the new phenotypes and mechanisms of developing mental disorder. We found cerebral microvascular angiopathy. In order to verify the generality of this finding, we used a post-mortem brain from patients with schizophrenia and bipolar disorder, and identified angiopathy similar to the one seen in the model mice. We also found that the angiopathy was accompanied by an impaired glucose incorporation to brain parenchyma in our mice model. These phenotypes were prevented by continuous administration of non-steroidal anti-inflammatory drugs (NSAIDs) before the onset of the disease, and some psychiatric-like symptoms were also suppressed. Notably, the patients used in this study do not necessarily have a record of excessive sucrose intake. They developed psychiatric disorders under various stress circumstances, suggesting that psychiatric disorders are associated with angiopathy in the brain caused by various environmental stresses, including metabolic stress.

About the Tokyo Metropolitan Institute of Medical Science

The Tokyo Metropolitan Institute of Medical Science (TMIMS) is dedicated to advancing basic and medical research in order to improve human health and quality of life. Founded in 2011 through the consolidation of three medical institutes, TMIMS is funded by the Tokyo metropolitan government and supports basic research in molecular and cellular biology in areas including genome replication, protein degradation, and infectious and neurodegenerative diseases. TMIMS also supports the development of new technologies in areas such as genome editing, control of neural prostheses, and vaccine development, and clinical research in fields such as optimization of nursing care and development of new treatments for psychiatric, neurodegenerative and other diseases. By integrating top-down applied research with bottom-up basic research, a goal of TMIMS is to more efficiently translate basic research results into treatments beneficial for humankind. For more information about TMIMS, see http://www.igakuken.or.jp/english.

High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice

10-Nov-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:
Doesn't an excessive intake of simple sugar affect higher brain function? - EurekAlert

Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -…

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Market Size, Share & Trends Analysis Report by Product (Cell-based Immunotherapies, Gene Therapies), by Therapeutic Category (Cardiovascular, Oncology), and Segment Forecasts, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries.

For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders.

Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Regenerative Medicine Market Report Highlights

Key Topics Covered:

Market Variables, Trends, & Scope

Competitive Analysis

Covid-19 Impact Analysis

Regenerative Medicine Market: Product Business Analysis

Regenerative Medicine Market: Therapeutic Category Business Analysis

Regenerative Medicine Market: Regional Business Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kovhgl

Continue reading here:
Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -...

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Berkeley Lights, Inc. (BLI) and Encourages…

RADNOR, PA / ACCESSWIRE / December 25, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Berkeley Lights, Inc. ("Berkeley Lights") (NASDAQ:BLI). The action charges Berkeley Lights with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Berkeley Lights's materially misleading statements to the public, Berkeley Lights's investors have suffered significant losses.

CANNOT VIEW THIS VIDEO? PLEASE CLICK HERE

CLICK HERE TO SUBMIT YOUR BERKELEY LIGHTS LOSSES

LEAD PLAINTIFF DEADLINE: February 7, 2022

CLASS PERIOD: July 17, 2020 through September 14, 2021

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:

James Maro, Esq. (484) 270-1453 or Toll Free (844) 887-9500 or Email at info@ktmc.com

BERKELEY LIGHTS'SALLEGED MISCONDUCT

Berkeley Lights, headquartered in Emeryville, California, is a digital cell biology company that focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products.

On September 15, 2021, Scorpion Capital published an investigative report about Berkeley Lights titled, "Fleecing Customers And IPO Bagholders With A $2 Million Black Box That's A Clunker, While Insiders and Silicon Valley Bigwigs Race To Dump Stock. Just Another VC Pump at 27X Sales. Target Price: $0." The report criticized Berkeley Lights's technology and questioned the durability of Berkeley Lights's most important business relationships and its business growth plan. In addition, the report found that negative customer experiences had further crimped Berkeley Lights's growth potential. Specifically, the report detailed "a trail of customers who allege they were tricked,' misled, or over-promised into buying a $2 million lemon" and concluded that the "reality is so far from [Berkeley Lights's] grandiose hype that we believe its product claims and practices may constitute outright fraud."

Story continues

Following this news, Berkeley Lights's stock price fell nearly 30% over two trading days to close at $23.53 per share on September 16, 2021.

WHAT CAN I DO?

Berkeley Lights's investors may, no later than February 7, 2022, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. Kessler Topaz Meltzer & Check, LLP encourages Berkeley Lights's investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE

WHO CAN BE A LEAD PLAINTIFF?

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. At the end of the day, we have succeeded if the bad guys pay up, and if you recover your assets. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit http://www.ktmc.com.

CONTACT:Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500 (toll free)info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

View source version on accesswire.com: https://www.accesswire.com/679410/Kessler-Topaz-Meltzer-Check-LLP-Announces-a-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-Berkeley-Lights-Inc-BLI-and-Encourages-Investors-with-Significant-Losses-to-Contact-the-Firm

Go here to read the rest:
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Berkeley Lights, Inc. (BLI) and Encourages...